SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Results from studies related to Optimer Pharmaceuticals, Inc.'s lead developmental product candidates will be presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held at The Moscone Center in San Francisco on September 12-15, 2009.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Photo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO
http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.comOptimer Pharmaceuticals, Inc.
